Schonfeld Strategic Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-163,116	Closed	-$3.93M	–	2705
2023 Q1	$3.93M	Sell	163,116 -143,430	-47%	-$1.8M	0.04%	498
2022 Q4	$3.24M	Buy	+306,546	New	+$2.47M	0.03%	636
2021 Q3	–	Sell	-38,208	Closed	-$322K	–	2589
2021 Q2	$322K	Sell	38,208 -70,233	-65%	-$567K	﹤0.01%	1430
2021 Q1	$1.14M	Buy	+108,441	New	+$1.53M	0.01%	842
2019 Q3	–	Sell	-23,300	Closed	-$282K	–	1306
2019 Q2	$282K	Buy	+23,300	New	+$127K	0.01%	794

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Schonfeld Strategic Advisors's PRVB Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 163,116 shares — an estimated $3.93M sold.

Schonfeld Strategic Advisors first reported a position in PRVB in Q2 2019 and held it in 5 quarters. The position peaked at $3.93M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Schonfeld Strategic Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 163,116 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $3.93M.
Schonfeld Strategic Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
Schonfeld Strategic Advisors's Provention Bio, Inc. Common Stock position peaked at $3.93M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.